Trastornos de coagulación después de la vacunación ChAdIx1 nCov-19 contra la COVID-19

Bernal J, Andrews N, Gower C, Stowe J, Robertson C, Tessier E, et al. Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and mortality in older adults in England. medRxiv [Internet]. 2021 [citado el 19/04/2021]: 2021.03.01.21252652. Disponible: https://doi.org/10.1101/2021.03.01.21252652

Voysey M, Costa Clemens S, Madhi S, Weckx L, Folegatti P, Aley P, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet [Internet]. 2021 [citado el 19/04/2021]; 397(10277): 881-891. Disponible: https://linkinghub.elsevier.com/retrieve/pii/S0140673621004323

Agencia Europea de Medicamentos. Vacuna COVID-19 AstraZeneca: los beneficios aún superan los riesgos a pesar del posible vínculo con coágulos sanguíneos raros con plaquetas bajas en sangre [Internet]. 2021 [citado el 19/04/2021]. Disponible: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots

Medicherla C, Pauley R, de Havenon A, Yaghi S, Ishida K, Torres J. Cerebral venous sinus thrombosis in the covid-19 pandemic. Journal of Neuro-Ophthalmology [Internet]. 2020 [citado el 19/04/2021]; 40(4): 457-462. Disponible: https://pubmed.ncbi.nlm.nih.gov/33186264/?dopt=Abstract

EMA. Vacuna COVID-19 de AstraZeneca: EMA encuentra un posible vínculo con casos muy raros de coágulos de sangre inusuales con plaquetas bajas en sangre [Internet]. 2021 [citado 19/04/2021]. Disponible: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood

Greinacher A, Thiele T, Warkentin T, Weisser K, Kyrle P, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine [Internet]. 2021 [citado el 19/04/2021]: NEJMoa2104840. Disponible: http://www.nejm.org/doi/10.1056/NEJMoa2104840

Salud Pública de Inglaterra. Orientación: vacunación covid-19 y coagulación sanguínea [Internet]. 2021 [citado el 19/04/2021]. Disponible: https://www.gov.uk/government/publications/covid-19-vaccination-and-blood-clotting/covid-19-vaccination-and-blood-clotting

Hunter P. Thrombosis after covid-19 vaccination. BMJ [Internet]. 2021 [citado el 19/04/2021]; 373: 958. Disponible: https://www.bmj.com/lookup/doi/10.1136/bmj.n958

European Medicines Agency. AstraZeneca’s COVID-19 vaccine: benefits and risks in context [Internet]. 2021 [citado el 27/06/2021]. Disponible: https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-benefits-risks-context

Tobaiqy M, Elkout H, MacLure K. Analysis of Thrombotic Adverse Reactions of COVID-19 AstraZeneca Vaccine Reported to EudraVigilance Database. Vaccines [Internet]. 2021 [citado el 27/06/2021]; 9(4): 393. Disponible: https://www.mdpi.com/2076-393X/9/4/393